Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.16 | -0.13 | -0.13 |
| FCF Yield | -65.15% | 1.08% | -7.42% | -7.19% |
| EV / EBITDA | -0.63 | 20.65 | -11.96 | -12.05 |
| Quality | ||||
| ROIC | -186.80% | 8.04% | -57.93% | -93.68% |
| Gross Margin | 51.75% | 93.32% | 86.54% | 81.75% |
| Cash Conversion Ratio | 0.56 | 0.24 | 0.91 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 57.81% | – | 224.60% | -100.00% |
| Free Cash Flow Growth | -1,671.49% | 105.85% | -142.70% | -103.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | -4.16 | 0.28 | 0.61 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.66 | 0.31 | 0.00 |
| Cash Conversion Cycle | -23.58 | 271.70 | 679.61 | -30,688.08 |